162 related articles for article (PubMed ID: 35326640)
1. Targeting the Non-Canonical NF-κB Pathway in Chronic Lymphocytic Leukemia and Multiple Myeloma.
Burley TA; Kennedy E; Broad G; Boyd M; Li D; Woo T; West C; Ladikou EE; Ashworth I; Fegan C; Johnston R; Mitchell S; Mackay SP; Pepper AGS; Pepper C
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326640
[TBL] [Abstract][Full Text] [Related]
2. Regulation of Bcl-XL by non-canonical NF-κB in the context of CD40-induced drug resistance in CLL.
Haselager M; Thijssen R; West C; Young L; Van Kampen R; Willmore E; Mackay S; Kater A; Eldering E
Cell Death Differ; 2021 May; 28(5):1658-1668. PubMed ID: 33495554
[TBL] [Abstract][Full Text] [Related]
3. The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF-κB activation and induces apoptosis in chronic lymphocytic leukemia B cells.
Godbersen JC; Humphries LA; Danilova OV; Kebbekus PE; Brown JR; Eastman A; Danilov AV
Clin Cancer Res; 2014 Mar; 20(6):1576-89. PubMed ID: 24634471
[TBL] [Abstract][Full Text] [Related]
4. JAK-STAT signalling shapes the NF-κB response in CLL towards venetoclax sensitivity or resistance via Bcl-XL.
Haselager MV; Thijssen R; Bax D; Both D; De Boer F; Mackay S; Dubois J; Mellink C; Kater AP; Eldering E
Mol Oncol; 2023 Jun; 17(6):1112-1128. PubMed ID: 36550750
[TBL] [Abstract][Full Text] [Related]
5. Lipopolysaccharide-induced activation of NF-κB non-canonical pathway requires BCL10 serine 138 and NIK phosphorylations.
Bhattacharyya S; Borthakur A; Dudeja PK; Tobacman JK
Exp Cell Res; 2010 Nov; 316(19):3317-27. PubMed ID: 20466000
[TBL] [Abstract][Full Text] [Related]
6. Novel pyrrolobenzodiazepine benzofused hybrid molecules inhibit NF-κB activity and synergise with bortezomib and ibrutinib in hematological cancers.
Lewis T; Corcoran DB; Thurston DE; Giles PJ; Ashelford K; Walsby EJ; Fegan CD; Pepper AGS; Miraz Rahman K; Pepper C
Haematologica; 2021 Apr; 106(4):958-967. PubMed ID: 32381576
[TBL] [Abstract][Full Text] [Related]
7. Regulation of p53 and Rb links the alternative NF-κB pathway to EZH2 expression and cell senescence.
Iannetti A; Ledoux AC; Tudhope SJ; Sellier H; Zhao B; Mowla S; Moore A; Hummerich H; Gewurz BE; Cockell SJ; Jat PS; Willmore E; Perkins ND
PLoS Genet; 2014 Sep; 10(9):e1004642. PubMed ID: 25255445
[TBL] [Abstract][Full Text] [Related]
8. Expression and Activity of the NF-κB Subunits in Chronic Lymphocytic Leukaemia: A Role for RelB and Non-Canonical Signalling.
Mulligan EA; Tudhope SJ; Hunter JE; Clift AEG; Elliott SL; Summerfield GP; Wallis J; Pepper CJ; Durkacz B; Veuger S; Willmore E
Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835430
[TBL] [Abstract][Full Text] [Related]
9. A roadmap of constitutive NF-κB activity in Hodgkin lymphoma: Dominant roles of p50 and p52 revealed by genome-wide analyses.
de Oliveira KA; Kaergel E; Heinig M; Fontaine JF; Patone G; Muro EM; Mathas S; Hummel M; Andrade-Navarro MA; Hübner N; Scheidereit C
Genome Med; 2016 Mar; 8(1):28. PubMed ID: 26988706
[TBL] [Abstract][Full Text] [Related]
10. Canonical nuclear factor kappaB pathway inhibition blocks myeloma cell growth and induces apoptosis in strong synergy with TRAIL.
Romagnoli M; Desplanques G; Maïga S; Legouill S; Dreano M; Bataille R; Barillé-Nion S
Clin Cancer Res; 2007 Oct; 13(20):6010-8. PubMed ID: 17947462
[TBL] [Abstract][Full Text] [Related]
11. Involvement of a novel Rac/RhoA guanosine triphosphatase-nuclear factor-kappaB inducing kinase signaling pathway mediating angiotensin II-induced RelA transactivation.
Choudhary S; Lu M; Cui R; Brasier AR
Mol Endocrinol; 2007 Sep; 21(9):2203-17. PubMed ID: 17595324
[TBL] [Abstract][Full Text] [Related]
12. The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells.
Walsby E; Pearce L; Burnett AK; Fegan C; Pepper C
Oncotarget; 2012 May; 3(5):525-34. PubMed ID: 22619113
[TBL] [Abstract][Full Text] [Related]
13. Stabilization of basally translated NF-kappaB-inducing kinase (NIK) protein functions as a molecular switch of processing of NF-kappaB2 p100.
Qing G; Qu Z; Xiao G
J Biol Chem; 2005 Dec; 280(49):40578-82. PubMed ID: 16223731
[TBL] [Abstract][Full Text] [Related]
14. TACI induces cIAP1-mediated ubiquitination of NIK by TRAF2 and TANK to limit non-canonical NF-kappaB signaling.
Kanno Y; Sakurai D; Hase H; Kojima H; Kobata T
J Recept Signal Transduct Res; 2010 Apr; 30(2):121-32. PubMed ID: 20184394
[TBL] [Abstract][Full Text] [Related]
15. The proteasome inhibitor carfilzomib functions independently of p53 to induce cytotoxicity and an atypical NF-κB response in chronic lymphocytic leukemia cells.
Gupta SV; Hertlein E; Lu Y; Sass EJ; Lapalombella R; Chen TL; Davis ME; Woyach JA; Lehman A; Jarjoura D; Byrd JC; Lucas DM
Clin Cancer Res; 2013 May; 19(9):2406-19. PubMed ID: 23515408
[TBL] [Abstract][Full Text] [Related]
16. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) promotes glioma cell invasion through induction of NF-κB-inducing kinase (NIK) and noncanonical NF-κB signaling.
Cherry EM; Lee DW; Jung JU; Sitcheran R
Mol Cancer; 2015 Jan; 14(1):9. PubMed ID: 25622756
[TBL] [Abstract][Full Text] [Related]
17. Maximal adamantyl-substituted retinoid-related molecule-induced apoptosis requires NF-κB noncanonical and canonical pathway activation.
Farhana L; Dawson MI; Murshed F; Fontana JA
Cell Death Differ; 2011 Jan; 18(1):164-73. PubMed ID: 20671747
[TBL] [Abstract][Full Text] [Related]
18. Microenvironmental stromal cells abrogate NF-κB inhibitor-induced apoptosis in chronic lymphocytic leukemia.
Simon-Gabriel CP; Foerster K; Saleem S; Bleckmann D; Benkisser-Petersen M; Thornton N; Umezawa K; Decker S; Burger M; Veelken H; Claus R; Dierks C; Duyster J; Zirlik K
Haematologica; 2018 Jan; 103(1):136-147. PubMed ID: 29122993
[TBL] [Abstract][Full Text] [Related]
19. A Kinase Assay for Measuring the Activity of the NIK-IKK1 Complex Induced via the Noncanonical NF-κB Pathway.
Mukherjee T; Ratra Y; Banoth B; Deka A; Polley S; Basak S
Methods Mol Biol; 2021; 2366():165-181. PubMed ID: 34236638
[TBL] [Abstract][Full Text] [Related]
20. The novel nuclear factor-kappaB inhibitor LC-1 is equipotent in poor prognostic subsets of chronic lymphocytic leukemia and shows strong synergy with fludarabine.
Hewamana S; Lin TT; Jenkins C; Burnett AK; Jordan CT; Fegan C; Brennan P; Rowntree C; Pepper C
Clin Cancer Res; 2008 Dec; 14(24):8102-11. PubMed ID: 19088025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
